Jul 1, 2022 · J2779 is a valid 2025 HCPCS code for Injection, ranibizumab, via intravitreal implant (susvimo), 0.1 mg or just “ Inj, susvimo 0.1 mg ” for short, used in Medical care. Effective Jul 01, …

HCPCS CODE J2779 Injection, ranibizumab, via intravitreal implant (susvimo), 0.1 mg

Dec 19, 2025 · HCPCS Code: J2779 The Healthcare Common Procedure Coding System (HCPCS) is a set of unique alphanumeric codes used to report medical procedures and services to healthcare …

HCPCS Code J2779 for Injection, ranibizumab, via intravitreal implant (susvimo), 0.1 mg as maintained by CMS falls under Drugs, Administered by Inject

SUSVIMO Billing Direction Bill 20 units with J2779 for the 2-mg administered dose of SUSVIMO On a second line, bill 80 units using J2779 and the JW modifier for discarded drug†

Jul 1, 2022 · Susvimo is a medication aligned to the HCPCS J Code J2779 for billing, pricing, and reimbursement purposes in the United States. It is an ophthalmology drug administered via the …

Dec 5, 2025 · Need more information about J2779? Get access to fees, crosswalks, billing policies, similar codes and much more. Access to this feature is available in the following products:

Jul 1, 2022 · Free, official coding info for 2025 HCPCS J2779 - includes code properties, rules & notes nd more.

This code represents the administration of ranibizumab via an intravitreal implant, specifically Susvimo, at a dosage of 0.1 mg. This treatment is primarily used for certain retinal conditions, including age …

Healthcare Common Procedure Coding System code J2779 is a billing code utilized in medical documentation and insurance claims to describe a specific injectable medication.